Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE